GLP-1 meds are all the rage for weight loss nowadays, but not everyone can safely take the drugs to shed pounds. Invasive weight-loss surgeries can often be a tough sell, too.
More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug semaglutide, a new analysis finds.
A new guidance issued jointly by groups representing U.S. surgeons, anesthesiologists and gastroenterologists affirms that most people taking popular GLP-1 weight-loss meds can keep taking them in the weeks before a surgery.
As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds.
